Clinical Trials · NCT02980965
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Fudan University
- Enrollment
- 249
- Start date
- May 2013
- Locations
- 1 site, China
- Primary endpoint
- objective response rate (ORR)